CureVac N.V. (FRA:5CV)
Germany
· Delayed Price · Currency is EUR 4.392
-0.004 (-0.09%)
At close: Dec 4, 2025
CureVac Revenue
CureVac had revenue of 54.13M EUR in the quarter ending September 30, 2025, a decrease of -89.04%. This brings the company's revenue in the last twelve months to 70.74M, down -86.98% year-over-year. In the year 2024, CureVac had annual revenue of 535.18M with 895.54% growth.
Revenue (ttm)
70.74M
Revenue Growth
-86.98%
P/S Ratio
14.01
Revenue / Employee
78.25K
Employees
983
Market Cap
991.06M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck KGaA | 21.27B |
| Siemens Healthineers AG | 23.38B |
| Bayer Aktiengesellschaft | 45.87B |
| Fresenius SE & Co. KGaA | 22.45B |
| Sartorius Aktiengesellschaft | 3.52B |
| Fresenius Medical Care AG | 19.64B |
| Carl Zeiss Meditec AG | 2.18B |
| Fielmann Group AG | 2.42B |
CureVac News
- 2 days ago - BioNTech Secures Majority Of CureVac Shares As Exchange Offer Advances - Nasdaq
- 2 days ago - BioNTech Achieves Minimum Condition in CureVac Exchange Offer - GlobeNewsWire
- 8 days ago - CureVac N.V. (CVAC) Shareholder/Analyst Call Prepared Remarks Transcript - Seeking Alpha
- 9 days ago - BioNTech (BNTX) Moves Forward with CureVac Acquisition - GuruFocus
- 9 days ago - BioNTech (BNTX) Advances with Exchange Offer for CureVac Shares - GuruFocus
- 9 days ago - BioNTech’s exchange offer for German mRNA vaccine peer CureVac set to expire Dec. 3 - Seeking Alpha
- 10 days ago - CureVac Announces Voting Results of Extraordinary General Meeting - Accesswire
- 10 days ago - CureVac Reveals Key Voting Outcomes from Extraordinary Shareholder Meeting - Wallstreet:Online